NATIONAL CLINICAL EFFECTIVENESS COMMITTEE

National Patient Safety Office

An Roinn Sláinte
Department of Health

25 July 2023

Dear website visitor,

The following section within *The NCEC National Clinical Guideline (NCG) No. 29: Unexpected Intraoperative Life-Threatening Haemorrhage*, published in 2022, has today been updated.

Page 123, appendix 6.2 (full guideline)	Replace existing poster with updated poster with minor changes to graphics and to include placement of a HSE logo and NCEC logo and QR code directing to the gov.ie site on the poster in addition to showing Version 2 displayed on the Poster. The final column at the bottom of the Poster outlining the location and timeline to the availability of various blood products and drugs has been amended. The previous version stated IDARUCIZUMAB (PRAXBIND) together with an image of the drug and this has been amended to state Direct Oral Anticoagulant Agents (DOAC) guided by Haematologist and removing the previous image provided. In the previous version, a text box was provided to record the location and time to availability of the drug. This has been amended to provide 2 boxes to record the location of reversal anti-FXa and reversal of direct thrombin inhibitor.
Page 45, appendix 6.2 (summary report)	Replace existing poster with updated poster with minor changes to graphics and to include placement of a HSE logo and NCEC logo and QR code directing to the gov.ie site on the poster in addition to showing Version 2 displayed on the Poster. The final column at the bottom of the Poster outlining the location and timeline to the availability of various blood products and drugs has been amended. The previous version stated IDARUCIZUMAB (PRAXBIND) together with an image of the drug and this has been amended to state Direct Oral Anticoagulant Agents (DOAC) guided by Haematologist and removing the previous image provided. In the previous version, a text box was provided to record the location and time to availability of the drug. This has been amended to provide 2 boxes to record the location of reversal anti-FXa and reversal of direct thrombin inhibitor.
n/a	Add the poster as a standalone link on the guideline landing webpage on the Department of Health gov.ie website.

If you require the complete originally published NCEC guideline for any reason (e.g. research etc) please contact the Clinical Effectiveness Unit in the Department of Health. The relevant email is ncec@health.gov.ie

Thank you for your interest in the NCEC National Clinical Guidelines.
ENDS